Epidemiology and treatment of Cyclospora cayetanensis infection in Peruvian children

Clin Infect Dis. 1997 May;24(5):977-81. doi: 10.1093/clinids/24.5.977.

Abstract

Cyclospora cayetanensis was detected in fecal specimens from 63 (1.1%) of 5,836 Peruvian children studied over 2 years; the protozoan was detected by modified acid-fast staining and autofluorescence under ultraviolet light. The highest prevalence occurred among children between 2 and 4 years of age. Thirty-two percent (20) of the 63 C. cayetanensis-infected children were symptomatic. Nineteen infected children were enrolled in a double-blind, placebo-controlled trial of a 3-day course of trimethoprim-sulfamethoxazole (TMP-SMZ; 5/25 mg/[kg x d]). Children were followed up with daily stool examinations (mean number of samples examined per child +/- SE, 19 +/- 4). The mean duration of oocyst excretion +/- SE was 4.8 +/- 1.2 days for TMP-SMZ recipients compared with 12.1 +/- 6.1 days for placebo recipients (P < .02). The prevalence of C. cayetanensis infection decreases during winter months and as children age; it decreases precipitously by adulthood. In children in areas of endemicity, C. cayetanensis usually causes mild disease that is often asymptomatic. TMP-SMZ therapy significantly decreases the duration of oocyst excretion.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Age Distribution
  • Animals
  • Anti-Infective Agents / administration & dosage
  • Anti-Infective Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Coccidiosis / drug therapy*
  • Coccidiosis / epidemiology*
  • Coccidiosis / parasitology
  • Cross-Sectional Studies
  • Developing Countries*
  • Diarrhea / drug therapy*
  • Diarrhea / epidemiology*
  • Diarrhea / parasitology
  • Double-Blind Method
  • Eucoccidiida / drug effects*
  • Feces / parasitology
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Male
  • Peru / epidemiology
  • Prevalence
  • Risk Factors
  • Sex Distribution
  • Treatment Outcome
  • Trimethoprim, Sulfamethoxazole Drug Combination / administration & dosage
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use*

Substances

  • Anti-Infective Agents
  • Trimethoprim, Sulfamethoxazole Drug Combination